Aquestive Therapeutics (AQST) Capital Expenditures (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Capital Expenditures of $52000.0 for Q1 2026, down 61.48% year-over-year from $135000.0 in Q1 2025, and up 112.24% quarter-over-quarter from -$425000.0 in Q4 2025.
Aquestive Therapeutics (AQST) Capital Expenditures (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Capital Expenditures history runs 10 years deep, the most recent figure standing at $52000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 61.48% year-over-year to $52000.0; the TTM figure through Mar 2026 stood at -$31000.0 (down 111.7% YoY), while the FY2025 annual figure was $52000.0, down 67.3% from the prior year.
- Capital Expenditures for Q1 2026 stood at $52000.0, up from -$425000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $826000.0 in Q2 2023, with the low at -$979000.0 in Q4 2023.
- The 5-year median for Capital Expenditures is $78000.0 (2022), against an average of $80437.5.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures plunged 3865.38% in 2023, then soared 1350.0% in 2024.
- Aquestive Therapeutics' Capital Expenditures stood at $26000.0 in 2022, then slumped by 3865.38% to -$979000.0 in 2023, then jumped by 116.24% to $159000.0 in 2024, then slumped by 367.3% to -$425000.0 in 2025, then soared by 112.24% to $52000.0 in 2026.
- Business Quant data shows AQST's Capital Expenditures at $52000.0 in Q1 2026, -$425000.0 in Q4 2025, and $394000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Aquestive Therapeutics | 583.72 Mn | 583.72 Mn | 9.80 Mn | 212,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 212,000.00 |
| Jun 30, 2026 | 212,000.00 |
| Mar 31, 2026 | 52,000.00 |
| Mar 31, 2026 | 52,000.00 |
| Dec 31, 2025 | -425,000.00 |
| Dec 31, 2025 | -425,000.00 |
| Sep 30, 2025 | 394,000.00 |
| Sep 30, 2025 | 394,000.00 |
| Jun 30, 2025 | -52,000.00 |
| Jun 30, 2025 | -52,000.00 |
| Mar 31, 2025 | 135,000.00 |
| Mar 31, 2025 | 135,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Jun 30, 2024 | -29,000.00 |
| Jun 30, 2024 | -29,000.00 |
| Mar 31, 2024 | 29,000.00 |
| Mar 31, 2024 | 29,000.00 |
| Dec 31, 2023 | -979,000.00 |
| Dec 31, 2023 | -979,000.00 |